Product Data Sheet

PerCP/Cy5.5 anti-human HLA-DR

Catalog # / Size: 2408040 / 100 tests
2408035 / 25 tests

Clone: Tü36

Isotype: Mouse IgG2b, κ

Immunogen: Human PBL

Reactivity: Human

Preparation: The antibody was purified by affinity chromatography and conjugated with PerCP/Cyanine5.5 under optimal conditions. The solution is free of unconjugated PerCP/Cyanine5.5 and unconjugated antibody.

Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA (origin USA).

Concentration: Lot-specific

Human peripheral blood lymphocytes were stained with HLA-DR (clone Tü36) PerCP/Cy5.5 (filled histogram) or mouse IgG2b, κ PerC/Cy5.5 isotype control (open histogram).

Applications:

Applications: Flow Cytometry

Recommended Usage: Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

* PerCP/Cyanine5.5 has a maximum absorption of 482 nm and a maximum emission of 690 nm.

Application Notes: Additional reported applications (of relevant formats) includes Western blotting4, immunoprecipitation4, and *in vitro* blocking5. The LEAF™ purified antibody (Endotoxin <0.1 EU/microg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (contact our custom solutions team).

Application References:

1. Thorsby E. 1974. *Transplant. Rev.* 18:51.
2. Qvigstad E, *et al.* 1984. *Hum. Immunol.* 11:207.
3. Servenius B, *et al.* 1984. *EMBO J.* 3:3209.
4. Ottenhoff TH, *et al.* 1985. *H*

Description: HLA-DR is a heterodimeric cell surface glycoprotein comprised of an α (heavy) chain and a β (light) chain. They are expressed on B cells, activated T cells, monocytes/macrophages, dendritic cells, and other non-professional APCs. In conjunction with the CD3/TCR complex and CD4 molecules, HLA-DR is critical for efficient peptide presentation to CD4+ T cells. Variations in the HLA gene expression are crucial to graft survival.

Antigen References:

1. Thorsby E. 1974. *Transplant. Rev.* 18:51.
2. Qvigstad E, *et al.* 1984. *Hum. Immunol.* 11:207.
3. Servenius B, *et al.* 1984. *EMBO J.* 3:3209.
4. Ottenhoff TH, *et al.* 1985. *H*

Sony Biotechnology Inc. 1730 North First Street, San Jose, CA 95112 www.sonybiotechnology.com